![\"boxes](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/07\/672131550_highres.jpg\")
<\/p>\n <\/p>\n
Brazil, Canada and India are some of the first countries where the patents to GLP-1 drugs expire. <\/p>\n
Keystone-SDA <\/p>\n
Generic drug manufacturer Sandoz is continuing to expand its presence in the market for novel GLP-1 diabetes treatments. The Basel-based company has confirmed that a new semaglutide generic has been granted marketing authorisation in Brazil, according to a press release issued on Wednesday.\n<\/p>\n
Listen to the article <\/p>\n
Listening the article <\/p>\n
Toggle language selector <\/p>\n
English (US) <\/p>\n<\/li>\n
English (British) <\/p>\n<\/li>\n<\/ul>\n
Generated with artificial intelligence. <\/p>\n
This content was published on <\/p>\n
July 29, 2026 – 14:02\n<\/p>\n
+Get the most important news from Switzerland in your inbox<\/strong><\/a><\/p>\n According to the statement, the Brazilian medicines regulator Anvisa has authorised the product Owozy for the treatment of type 2 diabetes. The product is being developed by Adalvo and will be marketed by Sandoz in Brazil. The market launch is planned for the second half of 2026.<\/p>\n This arrangement ultimately allows Sandoz to enter the market more quickly and means it does not have to finance the entire development process on its own.<\/p>\n It is estimated that more than 16.5 million people in Brazil live with diabetes. The Brazilian market for GLP-1 agonists, which includes semaglutide, is estimated at around US$1.8 billion.<\/p>\n No impact on 2026 figures<\/p>\n According to Sandoz, the approval has no impact on the financial forecast for 2026. The expected market launch in the second half of the year is in line with Sandoz\u2019s expectations. A potential launch this year would not make a significant contribution to the business.<\/p>\n Owozy is one of the first new semaglutide treatment options to be authorised in Brazil. In the generics market in particular, it is important to be among the first suppliers to bring the new \u2013 usually much cheaper \u2013 products to market in order to secure as much market share as possible during the initial launch wave.<\/p>\n Alongside Brazil, Canada is one of the first countries in which patents for GLP-1 blockbusters are expiring \u2013 albeit initially only for the indication of diabetes. For companies such as Sandoz, this nevertheless presents an opportunity to gain initial experience and secure market share.<\/p>\n \n More<\/p>\n More <\/p>\n New treatments\n <\/p>\n Can Swiss pharma giant Roche reshape the obesity market? <\/p>\n This content was published on <\/p>\n Apr 2, 2026 <\/p>\n Swiss pharmaceutical firm Roche is investing billions in new obesity treatments in hopes of breaking into a highly competitive market. <\/p>\n <\/p>\n Read more: Can Swiss pharma giant Roche reshape the obesity market? With this latest announcement, Sandoz is continuing to consistently implement its GLP-1 strategy. It was only at the end of June that the company announced that the US Food and Drug Administration (FDA) had accepted two marketing authorisation applications for generic versions of the active ingredient tirzepatide, the active ingredient in Eli Lilly\u2019s blockbuster drugs Mounjaro and Zepbound.<\/p>\n +\u00a0How we produce English news<\/a> Articles in this story <\/p>\n","protected":false},"excerpt":{"rendered":"Brazil, Canada and India are some of the first countries where the patents to GLP-1 drugs expire. Keystone-SDA…\n","protected":false},"author":2,"featured_media":610914,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[274],"tags":[584,61528,32494,79,18,135,19,17,11,462,32495,6079],"class_list":["post-610913","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-article","tag-beat-healthcare-innovation","tag-beat-medicine-access","tag-business","tag-eire","tag-health","tag-ie","tag-ireland","tag-latest-news","tag-medication","tag-production-type-deepl-autotranslation","tag-sda-ready-to-publish"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/117006553272614877","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/610913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=610913"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/610913\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/610914"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=610913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=610913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=610913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"injection](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/07\/676660337_highres.jpg\")
<\/p>\n
\n <\/a><\/p>\n
Translated from German, reviewed by an\u00a0English Department<\/a>\u00a0journalist.\u00a0<\/p>\n